Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study
Authors:
- Daniele Roberto GiacobbeDaniele Roberto Giacobbe
- Michele MirabellaMMMichele Mirabella
- Matteo RinaldiMRMatteo Rinaldi
- Angela Raffaella LositoALAngela Raffaella Losito
- Francesca RaffaelliFRFrancesca Raffaelli
- Filippo Del PuenteFPFilippo Del Puente
- Carolina SaffiotiCSCarolina Saffioti
- Malgorzata MikulskaMMMalgorzata Mikulska
- Maddalena GiannellaMGMaddalena Giannella
- Pierluigi VialePVPierluigi Viale
- Mario TumbarelloMTMario Tumbarello
- Matteo BassettiMatteo Bassetti
Open Access
- 19 December 2021
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 10 (12) , 1554
Abstract
Colistin is a last-resort agent for the treatment of infections due to Gram-negative bacteria with difficult-to-treat resistance. The primary objective of this post hoc analysis of a cross-sectional study conducted in 22 Italian hospitals was to assess factors associated with inadequate intravenous colistin dosage. Overall, 187 patients receiving intravenous colistin were included in the analyses. Inadequate colistin dosages were administered in 27% of cases (50/187). In multivariable analysis, AKI (dummy variable with KDIGO stage 0 as a reference, odds ratio (OR) 3.98 with 95% confidence interval (CI) 1.48–10.74 for stage 1, OR 4.44 with 95% CI 1.17–16.93 for stage 2, OR 9.41 with 95% CI 1.59–55.70 for stage 3; overall p = 0.001) retained an independent association with inadequate colistin dosage, whereas the presence of a central venous catheter was associated with adequate colistin dosage (OR: 0.34 for inadequate dosage, 95% CI: 0.16–0.72, p = 0.004). These results were confirmed in an additional multivariable model with the center as a random effect. The association between AKI and inadequate dosage may reflect the perception of an increased risk of nephrotoxicity in patients with impaired renal function, which nonetheless should not be accompanied by dosage reductions beyond those recommended and could represent the target of dedicated antimicrobial stewardship efforts.Keywords
This publication has 12 references indexed in Scilit:
- Rescuing the Last-Line Polymyxins: Achievements and ChallengesPharmacological Reviews, 2021
- Therapeutic options for difficult-to-treat Acinetobacter baumanniiinfections: a 2020 perspectiveExpert Opinion on Pharmacotherapy, 2020
- Use of colistin in adult patients: A cross-sectional studyJournal of Global Antimicrobial Resistance, 2020
- Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use2019
- Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce ToxicityAntibiotics, 2019
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteriaExpert Review of Clinical Pharmacology, 2018
- Hypoalbuminemia as a predictor of acute kidney injury during colistin treatmentScientific Reports, 2018
- Dosing Guidance for Intravenous Colistin in Critically Ill PatientsClinical Infectious Diseases, 2016
- Colistin: still a lifesaver for the 21st century?Expert Opinion on Drug Metabolism & Toxicology, 2016